Vanguard Group Inc. Boosts Stake in Atara Biotherapeutics Inc (NASDAQ:ATRA)

Share on StockTwits

Vanguard Group Inc. grew its stake in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 4.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,011,596 shares of the biotechnology company’s stock after buying an additional 132,282 shares during the quarter. Vanguard Group Inc. owned 5.60% of Atara Biotherapeutics worth $60,563,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Oppenheimer & Co. Inc. grew its holdings in shares of Atara Biotherapeutics by 15.2% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 10,132 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 1,340 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Atara Biotherapeutics by 22.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 8,800 shares of the biotechnology company’s stock worth $356,000 after acquiring an additional 1,600 shares during the last quarter. Xact Kapitalforvaltning AB grew its holdings in Atara Biotherapeutics by 37.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 8,100 shares of the biotechnology company’s stock worth $322,000 after acquiring an additional 2,200 shares during the last quarter. New York State Common Retirement Fund grew its holdings in Atara Biotherapeutics by 6.3% in the 1st quarter. New York State Common Retirement Fund now owns 43,800 shares of the biotechnology company’s stock worth $1,741,000 after acquiring an additional 2,600 shares during the last quarter. Finally, Aperio Group LLC bought a new stake in Atara Biotherapeutics in the 2nd quarter worth $63,000. Hedge funds and other institutional investors own 91.79% of the company’s stock.

In related news, insider Joe Newell sold 3,500 shares of Atara Biotherapeutics stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $13.51, for a total transaction of $47,285.00. Following the completion of the transaction, the insider now directly owns 57,998 shares of the company’s stock, valued at approximately $783,552.98. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 7.00% of the company’s stock.

A number of equities research analysts have issued reports on ATRA shares. Jefferies Financial Group lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $15.00 in a report on Monday, September 16th. Cowen reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, September 13th. Citigroup set a $14.00 price target on shares of Atara Biotherapeutics and gave the stock a “hold” rating in a report on Monday, August 12th. BidaskClub lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 27th. Finally, ValuEngine raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $29.75.

Shares of ATRA opened at $13.35 on Friday. The firm’s 50-day moving average price is $14.10 and its 200-day moving average price is $21.63. The company has a quick ratio of 7.80, a current ratio of 7.80 and a debt-to-equity ratio of 0.06. Atara Biotherapeutics Inc has a 1-year low of $11.50 and a 1-year high of $43.94.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.15). Sell-side analysts anticipate that Atara Biotherapeutics Inc will post -5.71 earnings per share for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: How does a 12b-1 fee affect fund performance?

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.